Related Experiment Video
Updated: May 28, 2025
09:53
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
3.5K
Targeted treatment for craniopharyngioma
Natalie E Stec1, Fred G Barker2, Priscilla K Brastianos3
1Divisions of Neuro-Oncology and Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Journal of Neuro-Oncology
|February 14, 2025
Summary
Targeted therapies show promise for craniopharyngioma treatment. BRAF/MEK inhibitors are effective for papillary craniopharyngioma (PCP), while Wnt pathway inhibitors are under investigation for adamantinomatous craniopharyngioma (ACP).
Area of Science:
- Oncology
- Molecular Biology
- Neuro-oncology
Background:
- Craniopharyngioma, a rare tumor of the hypothalamopituitary region, presents in adamantinomatous (ACP) and papillary (PCP) types.
- Conventional treatments risk neurological deficits; targeted therapies offer new hope.
- Genetic discoveries reveal BRAF-V600E mutations in PCP and CTNNB1/Wnt alterations in ACP.
Purpose of the Study:
- To review current targeted treatment strategies for papillary and adamantinomatous craniopharyngioma.
- To highlight advancements in molecularly targeted therapies for these rare tumors.
Main Methods:
- Review of clinical trial data and case studies on targeted therapies for craniopharyngioma.
- Analysis of pre-clinical research on Wnt pathway inhibitors for ACP.
Main Results:
- BRAF/MEK inhibition demonstrates durable tumor response in PCP across multiple studies and a phase II trial.
- CTNNB1/Wnt pathway inhibitors show promise in pre-clinical studies for ACP and are under ongoing investigation.
Conclusions:
- BRAF/MEK inhibition supports targeted therapy for newly diagnosed PCP.
- Further research is needed to establish optimal combinations, timing, and sequencing of targeted therapies with conventional treatments for both craniopharyngioma types.
